An Open Label Study to Discover Biomarkers of Intestinal Mucosal Healing in Crohn's Disease (CD)

Trial Profile

An Open Label Study to Discover Biomarkers of Intestinal Mucosal Healing in Crohn's Disease (CD)

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Infliximab (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Oct 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 03 Aug 2015 Planned End Date changed from 1 Oct 2015 to 1 Sep 2015, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top